* CNS invasion in AML: Lancet 1986; 2(8518): 1236-41
* CNS invasion in AML: Leukemia 1992; 6(7): 708-714)
* Pulmonary events at diagnosis of AML: Moreau et al. Leuk Lymphoma 2014; 55(11): 2556-63
* Timing of therapy: Rollig et al. Blood 2020; 136: 823-30
* ELN 2017 recommendations for diagnosis and treatment of AML: Blood. 2017 Jan 26;129(4):424-447
* Germline predisposition in myeloid malignancies: Klco and Mullighan. Nat Rev Cancer 2021; 21: 122-137
* Fernandez et al. NEJM 2009; 361: 1249-1259: ECOG study
* Burnett et al. Blood 2015: MRC AML 17 trial (Blood, April 2015):
* Burnett et al. Blood, 2016: Blood. 2016 Jul 21;128(3):449-52
* Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, et al. (2013) Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia. PLoS Onev 2013; 8(4):e60699
* Dauno vs ida: meta-analyse: Wang et al. Medicine 2020; 99: 24
* Dauno 90 vs ida 12 in FLT3+: Lee et al. J Clin Oncol 2017
* Dosing cytarabine:  [**High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis**](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110153)
Li W, Gong X, Sun M, Zhao X, Gong B, et al. (2014) High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis. PLOS ONE 9(10): e110153. <https://doi.org/10.1371/journal.pone.0110153>
* FLAG-IDA: Burnett et al. JCO 2013; 31: 3360-3368
* Midostaurin in 1st line in combination with chemotherapy for AML: Stone et al. N Engl J Med 2017; 377(5):454-464
* Gemtuzumab Ozogamicin in 1st line AML: ALFA0701 study: Lambert J. et al. Haematologica 2019; 104 (1): 113-119
* GO: meta-analyse: Hills et al. Lancet Oncol 2014; 15: 986-996
* CPX-351: Lancet et al. J Clin Oncol 2018; 36 (26): 2684-2692
* Early blast clearance: Bertoli et al. Haematologica 2014; 99(1):46-53
* Indications for allo SCT in AML: JAMA 2009; 301(22): 2349-2361
* Autologous SCT in AML: Cornelissen et al. Leukemia 2014 , 1-10
* Burnett et al. MRC AML15 Trial J Clin Oncol 2013; 31(27): 3360-8
* Oral azacitidin maintenance: N Engl J Med. 2020 Dec 24;383(26):2526-2537
* NPM1 MRD: Balsat et al. J Clin Oncol 2017
* NPM1 MRD: Ivey A et al. N Engl J Med 2016;374:422-433.
* Admiral trial: Gilteritinib in relapse AML: N Engl J Med. 2019 Oct 31;381(18):1728-1740
* Quantum-R trial: quizartinib in relapse AML: Cortes et al. Lancet Oncol. 2019 Jul;20(7):984-997
* HMA in relapse AML: Stahl et al. Blood Adv 2018; 2: 923-32